SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization

Genes and Development

Volumn 27, Issue 3, 2013, Pages 274-287

  Yi, Ping ^a   Xia, Weiya ^b   Wu, Ray Chang ^c   Lonard, David M ^a   Hung, Mien Chie ^b   O'Malley, Bert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Deubiquitination; HAUSP; p53; Resistance; SRC 3; TRAF4

Indexed keywords

HERPESVIRUS ASSOCIATED UBIQUITIN SPECIFIC PROTEASE; PROTEIN P53; PROTEINASE; STEROID RECEPTOR COACTIVATOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; CELL FUNCTION; CELL STRESS; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STABILITY; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MICE; NUCLEAR RECEPTOR COACTIVATOR 3; PROTEIN BINDING; PROTEIN STABILITY; STRESS, PHYSIOLOGICAL; TNF RECEPTOR-ASSOCIATED FACTOR 4; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84873519649     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.203760.112     Document Type: Article

References (52)

1. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. 1997. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968.
2. Bazzett LB, Watkins CS, Gercel-Taylor C, Taylor DD. 1999. Modulation of proliferation and chemosensitivity by procathepsin D and its peptides in ovarian cancer. Gynecol Oncol 74: 181-187.
3. Bradley JR, Pober JS. 2001. Tumor necrosis factor receptorassociated factors (TRAFs). Oncogene 20: 6482-6491.
4. Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, et al. 2010. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res 70: 6477-6485.
5. Camilleri-Broet S, Cremer I, Marmey B, Comperat E, Viguie F, Audouin J, Rio MC, Fridman WH, Sautes-Fridman C, Regnier CH. 2007. TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 26: 142-147.
6. Camp RL, Rimm EB, Rimm DL. 1999. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86: 2259-2265.
7. Cherfils-Vicini J, Vingert B, Varin A, Tartour E, Fridman WH, Sautes-Fridman C, Regnier CH, Cremer I. 2008. Characterization of immune functions in TRAF4-deficient mice. Immunology 124: 562-574.
8. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjonsberg G, Aas T, et al. 2011. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS ONE 6: e19249.
9. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, and Vogelstein B. 2004. Tumour suppression: Disruption of HAUSP gene stabilizes p53. Nature doi: 10.1038/nature02501.
10. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. 2012. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352.
11. Dihge L, Bendahl PO, Grabau D, Isola J, Lovgren K, Ryden L, Ferno M. 2008. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 109: 255-262.
12. Epping MT, Meijer LA, Krijgsman O, Bos JL, Pandolfi PP, Bernards R. 2011. TSPYL5 suppresses p53 levels and function by physical interaction with USP7. Nat Cell Biol 13: 102-108.
13. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, et al. 2009. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 15: 1417-1427.
14. Gasco M, Yulug IG, Crook T. 2003. TP53 mutations in familial breast cancer: Functional aspects. Hum Mutat 21: 301-306.
15. Glauner H, Siegmund D, Motejadded H, Scheurich P, Henkler F, Janssen O, Wajant H. 2002. Intracellular localization and transcriptional regulation of tumor necrosis factor (TNF) receptor-associated factor 4 (TRAF4). Eur J Biochem 269: 4819-4829.
16. Gojis O, Rudraraju B, Alifrangis C, Krell J, Libalova P, Palmieri C. 2010. The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease. Eur J Surg Oncol 36: 224-229.
17. Harper CE, Cook LM, Patel BB, Wang J, Eltoum IA, Arabshahi A, Shirai T, Lamartiniere CA. 2009. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 69: 1668-1682.
18. He LR, Liu MZ, Li BK, Rao HL, Deng HX, Guan XY, Zeng YX, Xie D. 2009. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci 100: 1591-1596.
19. Hu M, Gu L, Li M, Jeffrey PD, Gu W, Shi Y. 2006. Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: Implications for the regulation of the p53-MDM2 pathway. PLoS Biol 4: e27.
20. Janicke RU, Sprengart ML, Wati MR, Porter AG. 1998. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360.
21. Kedinger V, Rio MC. 2007. TRAF4, the unique family member. Adv Exp Med Biol 597: 60-71.
22. Kedinger V, Alpy F, Baguet A, Polette M, Stoll I, Chenard MP, Tomasetto C, Rio MC. 2008. Tumor necrosis factor receptorassociated factor 4 is a dynamic tight junction-related shuttle protein involved in epithelium homeostasis. PLoS ONE 3: e3518.
23. Kirkegaard T, McGlynn LM, Campbell FM, Muller S, Tovey SM, Dunne B, Nielsen KV, Cooke TG, Bartlett JM. 2007. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 13: 1405-1411.
24. Krajewska M, Krajewski S, Zapata JM, Van Arsdale T, Gascoyne RD, Berern K, McFadden D, Shabaik A, Hugh J, Reynolds A, et al. 1998. TRAF-4 expression in epithelial progenitor cells. Analysis in normal adult, fetal, and tumor tissues. Am J Pathol 152: 1549-1561.
25. Kuang SQ, Liao L, Zhang H, Lee AV, O'Malley BW, Xu J. 2004. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 64: 1875-1885.
26. Lee SK, Kim HJ, Na SY, Kim TS, Choi HS, Im SY, Lee JW. 1998. Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J Biol Chem 273: 16651-16654.
27. Leto G, Tumminello FM, Crescimanno M, Flandina C, Gebbia N. 2004. Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications. Clin Exp Metastasis 21: 91-106.
28. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, Gu W. 2002. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648-653.
29. Li M, Brooks CL, Kon N, Gu W. 2004. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13: 879-886.
30. Li R, Chen Y, Shu WX, Chen Z, Ke WJ. 2009a. Involvement of SRC-3 in deguelin-induced apoptosis in Jurkat cells. Int J Hematol 89: 628-635.
31. Li R, Chen Y, Zeng LL, Shu WX, Zhao F, Wen L, Liu Y. 2009b. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells. Toxicology 262: 98-105.
32. Longley DB, Johnston PG. 2005. Molecular mechanisms of drug resistance. J Pathol 205: 275-292.
33. Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, Abraham TE, Dirks RW, Jochemsen AG. 2005. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 18: 565-576.
34. Murphy LC, Simon SL, Parkes A, Leygue E, Dotzlaw H, Snell L, Troup S, Adeyinka A, Watson PH. 2000. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res 60: 6266-6271.
35. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. 2003. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361.
36. Regnier CH, Tomasetto C, Moog-Lutz C, Chenard MP, Wendling C, Basset P, Rio MC. 1995. Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem 270: 25715-25721.
37. Regnier CH, Masson R, Kedinger V, Textoris J, Stoll I, Chenard MP, Dierich A, Tomasetto C, Rio MC. 2002. Impaired neural tube closure, axial skeleton malformations, and tracheal ring disruption in TRAF4-deficient mice. Proc Natl Acad Sci 99: 5585-5590.
38. Rothe M, Wong SC, Henzel WJ, Goeddel DV. 1994. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78: 681-692.
39. Saridakis V, Sheng Y, Sarkari F, Holowaty MN, Shire K, Nguyen T, Zhang RG, Liao J, Lee W, Edwards AM, et al. 2005. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1: Implications for EBVmediated immortalization. Mol Cell 18: 25-36.
40. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. 2002. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4: 842-849.
41. Sheng Y, Saridakis V, Sarkari F, Duan S, Wu T, Arrowsmith CH, Frappier L. 2006. Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol 13: 285-291.
42. Tan TT, White E. 2008. Therapeutic targeting of death pathways in cancer: Mechanisms for activating cell death in cancer cells. Adv Exp Med Biol 615: 81-104.
43. Torres-Arzayus MI, De Mora JF, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, Brown M. 2004. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6: 263-274.
44. Wu MY, Fu J, Xu J, O'Malley BW, Wu RC. 2012. Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor. Cell Res 22: 1003-1021.
45. Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP, Hung MC. 2004. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10: 3815-3824.
46. Xu J, Wu RC, O'Malley BW. 2009. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9: 615-630.
47. Yan J, Tsai SY, Tsai MJ. 2006. SRC-3/AIB1: Transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 27: 387-394.
48. Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, Yu-Lee LY, Tsai SY, Tsai MJ. 2008. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res 68: 5460-5468.
49. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, et al. 2009. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325: 1134-1138.
50. Zapata JM, Pawlowski K, Haas E, Ware CF, Godzik A, Reed JC. 2001. A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem 276: 24242-24252.
51. Zhao C, Yasui K, Lee CJ, Kurioka H, Hosokawa Y, Oka T, Inazawa J. 2003. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 98: 18-23.
52. Zotti T, Uva A, Ferravante A, Vessichelli M, Scudiero I, Ceccarelli M, Vito P, Stilo R. 2011. TRAF7 protein promotes Lys-29-linked polyubiquitination of IkB kinase (IKKg)/NF-kB essential modulator (NEMO) and p65/RelA protein and represses NF-kB activation. J Biol Chem 286: 22924-22933.